DCAL Dishman Carbogen Amcis Q1 FY26 results (Apr–Jun 2025) and concall
Dishman Carbogen Amcis reported a strong Q1 FY26, driven by robust performance in its CDMO segment and improved profitability in Marketable Molecules. The company achieved significant revenue and EBITDA growth, alongside a reduction in net debt. Regulatory successes, including a clean USFDA inspection at Naroda and GMP certification for its French subsidiary, underscore operational excellence and open new growth avenues, particularly in the Chinese market and soft-gel drug products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 93 | 97 | 106 | 63 |
| EBITDA | 13 | 23 | 21 | 3 |
| Net profit | 14 | -13 | -7 | 3 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
